Takeda and Innovent Biologics Establish Global Oncology Partnership Beyond Greater China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 22 2025
0mins
Should l Buy TAK?
Source: NASDAQ.COM
Collaboration Agreement: Takeda has entered into a licensing and collaboration agreement with Innovent Biologics to develop and commercialize two late-stage oncology therapies, IBI363 and IBI343, globally excluding Greater China, with Takeda also having an option for IBI3001.
Therapy Details: IBI363 is being evaluated for non-small cell lung and colorectal cancers, while IBI343 targets Claudin 18.2 in gastric and pancreatic cancers. IBI3001 is a bispecific ADC currently in Phase 1 trials for various solid tumors.
Financial Terms: Innovent will receive a $1.2 billion upfront payment, including a $100 million equity investment from Takeda, along with potential milestone and royalty payments based on the success of the therapies.
Commercialization Structure: Takeda and Innovent will share costs and profits for IBI363 in the U.S., while Takeda will lead commercialization efforts outside the U.S. and Greater China, and will have global manufacturing rights for IBI363.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 17.890
Low
18.00
Averages
18.00
High
18.00
Current: 17.890
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iambic Signs $1.7B Multi-Year Deal with Takeda for AI Drug Development
- Agreement Scale: Iambic's multi-year agreement with Takeda is potentially worth over $1.7 billion, indicating a deep collaboration in small molecule drug development that is expected to significantly enhance Iambic's market position and revenue growth.
- Technology Application: The partnership will leverage Iambic's AI drug discovery models, focusing on small molecule drugs in gastrointestinal and inflammation therapeutic areas, highlighting the importance and application prospects of AI technology in biopharmaceuticals.
- Financial Gains: Under the terms, Iambic is set to receive upfront research costs and technology access fees, along with milestone payments that could exceed $1.7 billion, providing robust support for the company's financial stability and future investments.
- Royalty Rights: Iambic will also earn royalties on net sales of any products commercialized under the agreement, creating a continuous revenue stream that enhances its long-term growth potential in the competitive biopharmaceutical market.
See More
Takeda (TAK) Q2 2025 Earnings Call Transcript
See More
Alvotech's AVT80 Biosimilar Study Achieves Success
- Clinical Trial Success: Alvotech's AVT80 biosimilar achieved primary endpoints in the AVT80-GL-P01 trial, demonstrating pharmacokinetic similarity to Takeda's Entyvio, which is expected to enhance its competitiveness in the bowel disease treatment market.
- Significant Market Potential: With Entyvio generating $6.4 billion in global net revenue last year, Alvotech's success could capture substantial market share, especially as biosimilars gain increasing attention in the pharmaceutical landscape.
- Positive Regulatory Feedback: Regulatory feedback indicates that the AVT80-GL-P01 trial results meet expectations, confirming pharmacokinetic similarity for AVT80 and AVT16 in subcutaneous and intravenous administration, laying a solid foundation for future market applications.
- Positive Stock Reaction: Following the announcement, Alvotech shares spiked approximately 3% in premarket trading, reflecting investor optimism regarding the biosimilar's prospects, which may further drive the company's financing and expansion plans.
See More
Takeda Pharmaceutical Q3 2025 Earnings Report Analysis
- Earnings Miss: Takeda reported an adjusted net profit of 235 billion yen (approximately $1.53 billion) for Q3 2025, with earnings per American Depositary Share (EPADS) at 47 cents, falling short of analyst expectations of 55 cents, indicating pressure on profitability.
- Sales Decline: Total sales for the quarter reached $7.60 billion (1.192 trillion yen), missing consensus estimates of $8.53 billion, with a year-over-year sales decline of 4.2%, primarily due to decreased revenue in the Neuroscience segment.
- Mixed Product Performance: Neuroscience sales fell 23.6% to 108.4 billion yen, while vaccine sales nearly doubled to 23.3 billion yen, and cancer drug sales increased by 3.8% to 148.8 billion yen, highlighting disparities in market performance across different product lines.
- Guidance Revision: Takeda revised its fiscal 2025 core revenue guidance from 4.50 trillion yen to 4.53 trillion yen, expecting core operating profit of 1.15 trillion yen, reflecting proactive adjustments in cost management and favorable foreign exchange conditions.
See More
Takeda Updates FY2025 Revenue Guidance Amid Cost Discipline
- Performance Overview: Takeda reported a Non-GAAP EPS of ¥428.00 and revenue of ¥3,411.2 billion for the nine months ended, reflecting a 3.3% year-over-year decline, indicating pressure in the competitive pharmaceutical market.
- Fiscal Year Guidance Update: The company revised its FY2025 management guidance primarily due to VYVANSE, projecting core revenue to remain broadly flat, with low-single-digit declines in operating profit and EPS, showcasing its focus on cost discipline.
- Core Financial Forecasts: The revised core revenue forecast for FY2025 is set at ¥4,530 billion, with operating profit expected at ¥410 billion, demonstrating the company's ability to maintain profitability amid market uncertainties.
- Cash Flow and Dividends: Adjusted free cash flow is projected between ¥650 billion and ¥750 billion, while the annual dividend per share remains at ¥200, indicating stability in shareholder returns amidst operational challenges.
See More
Takeda Reports Q3 FY2025 Earnings Results with Updated Guidance
- Revenue Performance: Takeda's Q3 FY2025 revenue reached ¥3,411.2 billion, a 3.3% year-on-year decline primarily due to VYVANSE generics; however, the company raised its full-year forecasts based on cost discipline and favorable FX effects.
- Profit Growth: The operating profit for Q3 was ¥422.4 billion, reflecting a 1.2% increase year-on-year, demonstrating the effectiveness of the company's operational efficiency improvements and cost management, with expectations to meet core operating profit guidance.
- New Drug Applications: Takeda has submitted NDAs for oveporexton and rusfertide, with plans to file for zasocitinib within the next 18 months, each having the potential to redefine care standards and drive long-term growth for the company.
- Strategic Positioning: CFO Milano Furuta emphasized that FY2025 is pivotal for Takeda as the company prepares for multiple innovative product launches aimed at improving patient lives and delivering long-term shareholder value.
See More
Iambic Signs $1.7B Multi-Year Deal with Takeda for AI Drug Development
- Agreement Scale: Iambic's multi-year agreement with Takeda is potentially worth over $1.7 billion, indicating a deep collaboration in small molecule drug development that is expected to significantly enhance Iambic's market position and revenue growth.
- Technology Application: The partnership will leverage Iambic's AI drug discovery models, focusing on small molecule drugs in gastrointestinal and inflammation therapeutic areas, highlighting the importance and application prospects of AI technology in biopharmaceuticals.
- Financial Gains: Under the terms, Iambic is set to receive upfront research costs and technology access fees, along with milestone payments that could exceed $1.7 billion, providing robust support for the company's financial stability and future investments.
- Royalty Rights: Iambic will also earn royalties on net sales of any products commercialized under the agreement, creating a continuous revenue stream that enhances its long-term growth potential in the competitive biopharmaceutical market.
See More
Takeda (TAK) Q2 2025 Earnings Call Transcript
See More
Alvotech's AVT80 Biosimilar Study Achieves Success
- Clinical Trial Success: Alvotech's AVT80 biosimilar achieved primary endpoints in the AVT80-GL-P01 trial, demonstrating pharmacokinetic similarity to Takeda's Entyvio, which is expected to enhance its competitiveness in the bowel disease treatment market.
- Significant Market Potential: With Entyvio generating $6.4 billion in global net revenue last year, Alvotech's success could capture substantial market share, especially as biosimilars gain increasing attention in the pharmaceutical landscape.
- Positive Regulatory Feedback: Regulatory feedback indicates that the AVT80-GL-P01 trial results meet expectations, confirming pharmacokinetic similarity for AVT80 and AVT16 in subcutaneous and intravenous administration, laying a solid foundation for future market applications.
- Positive Stock Reaction: Following the announcement, Alvotech shares spiked approximately 3% in premarket trading, reflecting investor optimism regarding the biosimilar's prospects, which may further drive the company's financing and expansion plans.
See More
Takeda Pharmaceutical Q3 2025 Earnings Report Analysis
- Earnings Miss: Takeda reported an adjusted net profit of 235 billion yen (approximately $1.53 billion) for Q3 2025, with earnings per American Depositary Share (EPADS) at 47 cents, falling short of analyst expectations of 55 cents, indicating pressure on profitability.
- Sales Decline: Total sales for the quarter reached $7.60 billion (1.192 trillion yen), missing consensus estimates of $8.53 billion, with a year-over-year sales decline of 4.2%, primarily due to decreased revenue in the Neuroscience segment.
- Mixed Product Performance: Neuroscience sales fell 23.6% to 108.4 billion yen, while vaccine sales nearly doubled to 23.3 billion yen, and cancer drug sales increased by 3.8% to 148.8 billion yen, highlighting disparities in market performance across different product lines.
- Guidance Revision: Takeda revised its fiscal 2025 core revenue guidance from 4.50 trillion yen to 4.53 trillion yen, expecting core operating profit of 1.15 trillion yen, reflecting proactive adjustments in cost management and favorable foreign exchange conditions.
See More
Takeda Updates FY2025 Revenue Guidance Amid Cost Discipline
- Performance Overview: Takeda reported a Non-GAAP EPS of ¥428.00 and revenue of ¥3,411.2 billion for the nine months ended, reflecting a 3.3% year-over-year decline, indicating pressure in the competitive pharmaceutical market.
- Fiscal Year Guidance Update: The company revised its FY2025 management guidance primarily due to VYVANSE, projecting core revenue to remain broadly flat, with low-single-digit declines in operating profit and EPS, showcasing its focus on cost discipline.
- Core Financial Forecasts: The revised core revenue forecast for FY2025 is set at ¥4,530 billion, with operating profit expected at ¥410 billion, demonstrating the company's ability to maintain profitability amid market uncertainties.
- Cash Flow and Dividends: Adjusted free cash flow is projected between ¥650 billion and ¥750 billion, while the annual dividend per share remains at ¥200, indicating stability in shareholder returns amidst operational challenges.
See More
Takeda Reports Q3 FY2025 Earnings Results with Updated Guidance
- Revenue Performance: Takeda's Q3 FY2025 revenue reached ¥3,411.2 billion, a 3.3% year-on-year decline primarily due to VYVANSE generics; however, the company raised its full-year forecasts based on cost discipline and favorable FX effects.
- Profit Growth: The operating profit for Q3 was ¥422.4 billion, reflecting a 1.2% increase year-on-year, demonstrating the effectiveness of the company's operational efficiency improvements and cost management, with expectations to meet core operating profit guidance.
- New Drug Applications: Takeda has submitted NDAs for oveporexton and rusfertide, with plans to file for zasocitinib within the next 18 months, each having the potential to redefine care standards and drive long-term growth for the company.
- Strategic Positioning: CFO Milano Furuta emphasized that FY2025 is pivotal for Takeda as the company prepares for multiple innovative product launches aimed at improving patient lives and delivering long-term shareholder value.
See More
